GLP-1受容体作動薬の世界市場レポート 2025年

GLP-1受容体作動薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.7％で177億2,000万米ドルに成長します。予測期間の成長は、ライフスタイル管理の重視、個別化医療アプローチの拡大、適応症の拡大、次世代製品の開発、併用療法への統合などに起因すると考えられます。予測期間における主な動向としては、経口製剤のイントロダクション、併用療法への注力、戦略的パートナーシップと提携、償還政策とアクセス、患者中心のアプローチなどが挙げられます。

糖尿病の有病率の増加は、今後のGLP-1受容体作動薬市場の成長を牽引すると予測されます。糖尿病は、膵臓からのインスリン分泌が不足するか、分泌されたインスリンを体が有効に利用できない場合に発症する慢性疾患です。高血糖は、糖尿病として知られる代謝障害の主要な症状です。GLP-1受容体作動薬は糖尿病治療において利用され、体内でより多くのインスリンが分泌されるよう刺激し、血糖値を下げるのに役立ちます。その結果、糖尿病有病率の上昇が市場の成長を後押しします。例えば、2024年3月、英国の政府機関であるOffice for Health Improvement and Disparitiesのデータによると、2022年3月から2023年3月にかけて、1型糖尿病患者のうち推奨される8つのケアプロセスをすべて受けている人の割合は22％増加し、2型糖尿病患者の場合は21％増加しました。さらに、HbA1cの目標値を達成した人の割合は37.9%に上昇し、全国糖尿病監査（NDA）が報告した数値の中で過去最高を記録しました。したがって、糖尿病有病率の上昇がGLP-1受容体作動薬市場の成長を促進しています。

GLP-1受容体作動薬市場の成長は、肥満症例の増加によっても後押しされると予想されます。肥満は、体脂肪の過剰蓄積を特徴とする病状であり、さまざまな健康リスクと関連しています。GLP-1受容体作動薬は、食欲や血糖値を調節する天然由来のホルモンGLP-1の作用を模倣することで、肥満症の治療に有効であることを示しています。世界保健機関（WHO）の2022年3月の報告書によると、世界全体で10億人以上が肥満の影響を受けており、その内訳は成人6億5,000万人、青年3億4,000万人、小児3,900万人で、この数は増加の一途をたどっています。約1億6,700万人が、過体重または肥満のために健康を損なう可能性があると推定されています。したがって、肥満の有病率の増加がGLP-1受容体作動薬市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界GLP-1受容体作動薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界のGLP-1受容体作動薬市場：成長率分析
• 世界のGLP-1受容体作動薬市場の実績：規模と成長, 2019-2024
• 世界のGLP-1受容体作動薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界GLP-1受容体作動薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のGLP-1受容体作動薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エキセナチド
• リラグルチド
• デュラグルチド
• リキシセナチド
• その他の薬物
• 世界のGLP-1受容体作動薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口
• オーラル
• 世界のGLP-1受容体作動薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外科クリニック
• その他のユーザー
• 世界のGLP-1受容体作動薬市場、エクセナチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビエッタ
• ビデュレオン
• 世界のGLP-1受容体作動薬市場リラグルチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヴィクトザ
• サクセンダ
• 世界のGLP-1受容体作動薬市場デュラグルチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トルリシティ
• 世界のGLP-1受容体作動薬市場、リキシセナチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アドリキシン
• 世界のGLP-1受容体作動薬市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セマグルチド
• チルゼパチド
• その他

第7章 地域別・国別分析

• 世界のGLP-1受容体作動薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のGLP-1受容体作動薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• GLP-1受容体作動薬市場：競合情勢
• GLP-1受容体作動薬市場：企業プロファイル
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Hanmi Pharm Co. Ltd.
• Pfizer Inc.
• Amgen Inc.
• Innovent Biologics Inc.
• Jiangsu Hengrui Medicine Co.
• Sun Pharmaceuticals Industries Ltd.
• PegBio Co. Ltd.
• Zealand Pharma A/S
• Bristol-Myers Squibb Company
• Chongqing Lummy Pharmaceutical Co. Ltd.
• Daiichi Sankyo Company Limited
• Dong-A ST Co. Ltd.
• Eisai Co. Ltd.
• HanAll Biopharma Co. Ltd.
• Ipsen SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• GLP-1受容体作動薬市場2029：新たな機会を提供する国
• GLP-1受容体作動薬市場2029：新たな機会を提供するセグメント
• GLP-1受容体作動薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A GLP-1 receptor agonist is a type of medication designed to stimulate insulin release when blood glucose levels are elevated and to inhibit glucagon secretion in the presence of low blood glucose conditions. These medications are primarily employed in the treatment of type 2 diabetes mellitus.

The main drug class of GLP-1 receptor agonists includes liraglutide, dulaglutide, lixisenatide, and others. Liraglutide, for instance, is a GLP-1 receptor agonist that facilitates the release of an appropriate amount of insulin from the pancreas in response to elevated blood sugar levels. These medications are administered through parenteral and oral routes, commonly utilized in settings such as hospitals, surgical clinics, and other medical facilities.

The GLP-1 receptor agonist market research report is one of a series of new reports from The Business Research Company that provides GLP-1 receptor agonist market statistics, including GLP-1 receptor agonist industry global market size, regional shares, competitors with GLP-1 receptor agonist market share, detailed GLP-1 receptor agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the GLP-1 receptor agonist industry. This GLP-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The GLP-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.58 billion in 2024 to $14.22 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance, global health initiatives, patient preference for injectable therapies.

The GLP-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $17.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches.

The increasing prevalence of diabetes is anticipated to drive the growth of the GLP-1 receptor agonist market in the future. Diabetes is a chronic condition that occurs when the pancreas either produces insufficient insulin or when the body is unable to effectively utilize the insulin it produces. High blood sugar levels are a key symptom of the metabolic disorder known as diabetes mellitus. GLP-1 receptor agonists are utilized in diabetes treatment to stimulate the body to produce more insulin, thereby helping to lower blood sugar levels. As a result, the rising prevalence of diabetes will boost market growth. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. Additionally, the percentage of individuals achieving target HbA1c levels climbed to 37.9%, marking the highest figure ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is fueling the growth of the GLP-1 receptor agonist market.

The growth of the GLP-1 receptor agonist market is also expected to be boosted by the increasing cases of obesity. Obesity, a medical condition characterized by excessive body fat accumulation, is associated with various health risks. GLP-1 receptor agonists have shown effectiveness in treating obesity by mimicking the effects of the naturally occurring hormone GLP-1, which regulates appetite and blood sugar levels. According to the World Health Organization's March 2022 report, over 1 billion individuals globally are affected by obesity, including 650 million adults, 340 million adolescents, and 39 million children, with this number continuing to rise. It is estimated that around 167 million people may experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is contributing to the growth of the GLP-1 receptor agonist market.

A key trend gaining momentum in the GLP-1 receptor agonist market is product innovation, with major companies focusing on developing innovative solutions to strengthen their market position. For instance, in May 2022, Eli Lilly and Company launched Mounjaro, an FDA-approved GIP and GLP-1 receptor agonist designed using a single molecule to activate the body's receptors for incretin hormones. This product is available as a pen auto-injector with a pre-attached, hidden needle, providing convenience for patients.

Major companies in the GLP-1 receptor agonist market are concentrating on developing sustained-release GLP-1 receptor agonists to gain a competitive edge. Sustained-release GLP-1 receptor agonists slowly release the medication into the bloodstream, allowing for longer-lasting effects and less frequent injections compared to traditional GLP-1 receptor agonists. Mitsubishi Tanabe Pharma Corporation launched Mounjaro 2.5 mg or 5 mg Ateos in April 2023, which is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes.

In February 2022, Sanofi S.A. strengthened its position in the market by acquiring Amunix Pharmaceuticals Inc., a US-based immuno-oncology company developing GLP-1 receptor agonists and transformative therapies for cancer. The acquisition is expected to provide Sanofi access to various products and technologies, including next-generation conditionally activated biologics.

Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

GLP-1 Receptor Agonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glp-1 receptor agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glp-1 receptor agonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glp-1 receptor agonist market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Exenatide; Liraglutide; Dulaglutide; Lixisenatide; Other Drugs
• 2) By Route Of Administration: Parenteral; Oral
• 3) By End Users: Hospitals; Surgical Clinics; Other Users
• Subsegments:
• 1) By Exenatide: Byetta; Bydureon
• 2) By Liraglutide: Victoza; Saxenda
• 3) By Dulaglutide: Trulicity
• 4) By Lixisenatide: Adlyxin
• 5) By Other Drugs: Semaglutide; Tirzepatide; Others
• Companies Mentioned: Novo Nordisk A/S; Sanofi SA; Eli Lilly and Company; AstraZeneca Inc.; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. GLP-1 Receptor Agonist Market Characteristics

3. GLP-1 Receptor Agonist Market Trends And Strategies

4. GLP-1 Receptor Agonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global GLP-1 Receptor Agonist Growth Analysis And Strategic Analysis Framework

• 5.1. Global GLP-1 Receptor Agonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global GLP-1 Receptor Agonist Market Growth Rate Analysis
• 5.4. Global GLP-1 Receptor Agonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global GLP-1 Receptor Agonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global GLP-1 Receptor Agonist Total Addressable Market (TAM)

6. GLP-1 Receptor Agonist Market Segmentation

• 6.1. Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exenatide
• Liraglutide
• Dulaglutide
• Lixisenatide
• Other Drugs
• 6.2. Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• 6.3. Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Surgical Clinics
• Other Users
• 6.4. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Exenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Byetta
• Bydureon
• 6.5. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Victoza
• Saxenda
• 6.6. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Dulaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trulicity
• 6.7. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Lixisenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adlyxin
• 6.8. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Semaglutide
• Tirzepatide
• Others

7. GLP-1 Receptor Agonist Market Regional And Country Analysis

• 7.1. Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific GLP-1 Receptor Agonist Market

• 8.1. Asia-Pacific GLP-1 Receptor Agonist Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China GLP-1 Receptor Agonist Market

• 9.1. China GLP-1 Receptor Agonist Market Overview
• 9.2. China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India GLP-1 Receptor Agonist Market

• 10.1. India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan GLP-1 Receptor Agonist Market

• 11.1. Japan GLP-1 Receptor Agonist Market Overview
• 11.2. Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia GLP-1 Receptor Agonist Market

• 12.1. Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia GLP-1 Receptor Agonist Market

• 13.1. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea GLP-1 Receptor Agonist Market

• 14.1. South Korea GLP-1 Receptor Agonist Market Overview
• 14.2. South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe GLP-1 Receptor Agonist Market

• 15.1. Western Europe GLP-1 Receptor Agonist Market Overview
• 15.2. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK GLP-1 Receptor Agonist Market

• 16.1. UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany GLP-1 Receptor Agonist Market

• 17.1. Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France GLP-1 Receptor Agonist Market

• 18.1. France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy GLP-1 Receptor Agonist Market

• 19.1. Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain GLP-1 Receptor Agonist Market

• 20.1. Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe GLP-1 Receptor Agonist Market

• 21.1. Eastern Europe GLP-1 Receptor Agonist Market Overview
• 21.2. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia GLP-1 Receptor Agonist Market

• 22.1. Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America GLP-1 Receptor Agonist Market

• 23.1. North America GLP-1 Receptor Agonist Market Overview
• 23.2. North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA GLP-1 Receptor Agonist Market

• 24.1. USA GLP-1 Receptor Agonist Market Overview
• 24.2. USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada GLP-1 Receptor Agonist Market

• 25.1. Canada GLP-1 Receptor Agonist Market Overview
• 25.2. Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America GLP-1 Receptor Agonist Market

• 26.1. South America GLP-1 Receptor Agonist Market Overview
• 26.2. South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil GLP-1 Receptor Agonist Market

• 27.1. Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East GLP-1 Receptor Agonist Market

• 28.1. Middle East GLP-1 Receptor Agonist Market Overview
• 28.2. Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa GLP-1 Receptor Agonist Market

• 29.1. Africa GLP-1 Receptor Agonist Market Overview
• 29.2. Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. GLP-1 Receptor Agonist Market Competitive Landscape And Company Profiles

• 30.1. GLP-1 Receptor Agonist Market Competitive Landscape
• 30.2. GLP-1 Receptor Agonist Market Company Profiles
  • 30.2.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

31. GLP-1 Receptor Agonist Market Other Major And Innovative Companies

• 31.1. Hanmi Pharm Co. Ltd.
• 31.2. Pfizer Inc.
• 31.3. Amgen Inc.
• 31.4. Innovent Biologics Inc.
• 31.5. Jiangsu Hengrui Medicine Co.
• 31.6. Sun Pharmaceuticals Industries Ltd.
• 31.7. PegBio Co. Ltd.
• 31.8. Zealand Pharma A/S
• 31.9. Bristol-Myers Squibb Company
• 31.10. Chongqing Lummy Pharmaceutical Co. Ltd.
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Dong-A ST Co. Ltd.
• 31.13. Eisai Co. Ltd.
• 31.14. HanAll Biopharma Co. Ltd.
• 31.15. Ipsen SA

32. Global GLP-1 Receptor Agonist Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The GLP-1 Receptor Agonist Market

34. Recent Developments In The GLP-1 Receptor Agonist Market

35. GLP-1 Receptor Agonist Market High Potential Countries, Segments and Strategies

• 35.1 GLP-1 Receptor Agonist Market In 2029 - Countries Offering Most New Opportunities
• 35.2 GLP-1 Receptor Agonist Market In 2029 - Segments Offering Most New Opportunities
• 35.3 GLP-1 Receptor Agonist Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer